Nyxoah (NASDAQ:NYXH) Given New $18.00 Price Target at HC Wainwright

Nyxoah (NASDAQ:NYXH) had its price target cut by research analysts at HC Wainwright from $22.00 to $18.00 in a research report issued to clients and investors on Friday, Benzinga reports. The brokerage currently has a “buy” rating on the stock. HC Wainwright’s target price indicates a potential upside of 116.09% from the stock’s current price.

Several other equities research analysts also recently issued reports on NYXH. Piper Sandler lifted their price target on shares of Nyxoah from $15.00 to $20.00 and gave the stock an “overweight” rating in a research note on Wednesday, March 6th. Stifel Nicolaus reissued a “buy” rating and issued a $27.00 target price on shares of Nyxoah in a research report on Wednesday, May 15th. Oppenheimer dropped their target price on shares of Nyxoah from $20.00 to $15.00 and set an “outperform” rating for the company in a research report on Wednesday, May 15th. Finally, Cantor Fitzgerald dropped their target price on shares of Nyxoah from $18.00 to $17.00 and set an “overweight” rating for the company in a research report on Wednesday, May 15th. One analyst has rated the stock with a hold rating and five have given a buy rating to the company’s stock. According to MarketBeat.com, the stock presently has a consensus rating of “Moderate Buy” and a consensus price target of $19.40.

Nyxoah Stock Performance

Shares of NYXH stock opened at $8.33 on Friday. The company’s fifty day simple moving average is $11.37 and its 200-day simple moving average is $9.21. Nyxoah has a 52 week low of $4.00 and a 52 week high of $20.00. The company has a debt-to-equity ratio of 0.13, a current ratio of 3.94 and a quick ratio of 3.70.

Nyxoah (NASDAQ:NYXH) last issued its earnings results on Tuesday, March 5th. The company reported ($0.41) EPS for the quarter, meeting analysts’ consensus estimates of ($0.41). Nyxoah had a negative net margin of 843.49% and a negative return on equity of 42.14%. The business had revenue of $1.96 million for the quarter, compared to the consensus estimate of $2.01 million. On average, equities research analysts expect that Nyxoah will post -1.66 earnings per share for the current year.

Institutional Inflows and Outflows

An institutional investor recently bought a new position in Nyxoah stock. Ikarian Capital LLC bought a new stake in shares of Nyxoah S.A. (NASDAQ:NYXH) in the first quarter, according to its most recent Form 13F filing with the SEC. The fund bought 50,699 shares of the company’s stock, valued at approximately $684,000.

Nyxoah Company Profile

Nyxoah SA, a medical technology company, focuses on the development and commercialization of solutions to treat sleep disordered breathing conditions. The company's lead solution comprises Genio system, a CE-Marked, patient-centric, and hypoglossal neurostimulation therapy to treat moderate to severe obstructive sleep apnea.